Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.84 |
| ▸ | POLB | P06746 | 3/20 | 0.84 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.84 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.84 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.84 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.84 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.84 |
| ▸ | TOP2A | P11388 | 4/20 | 0.56 |
| ▸ | TOP2B | Q02880 | 4/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.53 |
| ▸ | GSK3B | P49841 | 6/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Orbifloxacin SCHEMBL125116 | 1.00 | MEN1 (1.00) | MEN1KMT2AKCNH2POLBCACNA1F | |
| Orbifloxacin SCHEMBL29420860 | 1.00 | MEN1 (1.00) | MEN1KMT2AKCNH2POLBCACNA1F | |
| SCHEMBL10584006 | 0.93 | MEN1 (0.86) | MEN1KMT2AKCNH2POLBCACNA1F | |
| SCHEMBL10584011 | 0.93 | MEN1 (0.86) | MEN1KMT2AKCNH2POLBCACNA1F | |
| Sparfloxacin SCHEMBL1387460 | 0.92 | KCNH2 (1.00) | MEN1KMT2AKCNH2POLBCACNA1F | |
| Sparfloxacin SCHEMBL2637186 | 0.92 | KCNH2 (1.00) | MEN1KMT2AKCNH2POLBCACNA1F | |
| Sparfloxacin SCHEMBL41311 | 0.92 | KCNH2 (1.00) | MEN1KMT2AKCNH2POLBCACNA1F | |
| Sparfloxacin SCHEMBL29365159 | 0.92 | KCNH2 (1.00) | MEN1KMT2AKCNH2POLBCACNA1F | |
| Sparfloxacin SCHEMBL9368141 | 0.91 | KCNH2 (0.98) | MEN1KMT2AKCNH2POLBCACNA1F | |
| Sparfloxacin SCHEMBL28087316 | 0.91 | KCNH2 (0.98) | MEN1KMT2AKCNH2POLBCACNA1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0375658-B1 | Quinoline derivatives and processes for preparation thereof | DAINIPPON PHARMACEUTICAL CO (JP) | 1994-08-03 | — | — | EP | claimed |
| EP-0284935-A1 | 5-Substituted quinolone- and naphthyridone carboxylic acid derivatives | BAYER AG (DE) | 1988-10-05 | — | — | EP | claimed |
| US-20090306035-A1 | Compounds and Methods for modulating the Silencing of a Polynucleotide of Interest | EMORY UNIVERSITY (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090306035-A1 | Compounds and Methods for modulating the Silencing of a Polynucleotide of Interest | EMORY UNIVERSITY (US) | 2009-12-10 | — | — | US | disclosed |
| EP-0342649-B1 | Improved process for the preparation of 5-amino-7-(substituted amino)-quinoline-3-carboxylic acids | WARNER LAMBERT CO (US) | 1994-11-30 | — | — | EP | disclosed |
| EP-0375658-B1 | Quinoline derivatives and processes for preparation thereof | DAINIPPON PHARMACEUTICAL CO (JP) | 1994-08-03 | — | — | EP | disclosed |
| EP-0375658-A1 | Quinoline derivatives and processes for preparation thereof | Dainippon Pharmaceutical Co., Ltd. (JP) | 1990-06-27 | — | — | EP | disclosed |
| US-4886810-A | ANTIBACTERIAL | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1989-12-12 | — | — | US | disclosed |
| EP-0342649-A2 | Improved process for the preparation of 5-amino-7-(substituted amino)-quinoline-3-carboxylic acids | WARNER-LAMBERT COMPANY (US) | 1989-11-23 | — | — | EP | disclosed |
| EP-0284935-A1 | 5-Substituted quinolone- and naphthyridone carboxylic acid derivatives | BAYER AG (DE) | 1988-10-05 | — | — | EP | disclosed |
| EP-0242789-A2 | Novel quinoline derivates and processes for preparation thereof | Dainippon Pharmaceutical Co., Ltd. (JP) | 1987-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306035-A1 | Compounds and Methods for modulating the Silencing of a Polynucleotide of Interest | SNRPE, NSUN2, SNRPA | MEN1 3571/4885KMT2A 1401/4885KCNH2 4758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.